A Phase 2 Study of Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone (LR-CD) for Untreated Low-Grade Non-Hodgkin Lymphoma Requiring Therapy

American Journal of Hematology - United States
doi 10.1002/ajh.24693

Related search